艾迪注射液辅助化疗治疗老年晚期非小细胞肺癌患者的疗效分析  

Efficacy analysis of adjuvant chemotherapy with Aidi injection in the treatment of advanced non-small cell lung cancer in the elderly

作　　者：廉士海[1] 龚淼[2] LIAN Shi-hai;GONG Miao(Outpatient Department,Zaozhuang Municipal Hospital,Zaozhuang 277100,China)

机构地区：[1]枣庄市立医院门诊部,277100 [2]枣庄市立医院光明路门诊部,277100

出　　处：《中国实用医药》2024年第18期1-4,共4页China Practical Medicine

摘　　要：目的探讨对老年晚期非小细胞肺癌患者给予艾迪注射液辅助化疗治疗的临床效果。方法62例老年晚期非小细胞肺癌患者,依据投掷硬币法分为参照组和研究组,各31例。参照组患者采用吉西他滨和顺铂(GP)化疗治疗,研究组患者在参照组基础上采用艾迪注射液治疗。比较两组患者治疗效果、免疫功能[CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)CD25^(+)调节性T细胞(Treg)]以及生存质量评分(生理层面、心理层面、社会层面、环境层面评分)。结果研究组客观有效率45.16%、疾病控制率87.10%均高于参照组的19.35%、54.84%(P<0.05)。治疗后,研究组CD3^(+)(55.65±7.86)%、CD4^(+)(36.29±5.49)%高于参照组的(50.16±8.42)%、(30.49±4.19)%,CD8^(+)(22.59±4.89)%、CD4^(+)CD25^(+)Treg(4.36±1.08)%低于参照组的(26.15±4.36)%、(8.15±1.39)%(P<0.05)。治疗后,研究组生理层面、心理层面、社会层面、环境层面评分分别为(70.33±3.12)、(71.44±3.25)、(71.64±5.22)、(71.87±4.25)分,高于参照组的(60.36±2.25)、(60.64±5.15)、(60.65±4.22)、(60.64±5.25)分(P<0.05)。结论临床对老年晚期非小细胞肺癌患者给予艾迪注射液辅助化疗治疗,可提升治疗效果以及生存质量,改善免疫功能,临床可推广应用。Objective To explore the clinical effect of adjuvant chemotherapy with Aidi injection in the treatment of advanced non-small cell lung cancer in the elderly.Methods 62 elderly patients with advanced non-small cell lung cancer were grouped into a reference group and a study group according to the coin tossing method,each consisting of 31 patients.Patients in the reference group were treated with gemcitabine and cisplatin(GP)chemotherapy,and patients in the study group were treated with Aidi injection based on the reference group.Patients in both groups were compared in terms of threapeutic effect,immune function[CD3^(+),CD4^(+),CD8^(+),CD4^(+)CD25^(+)regulatory T cells(Treg)]and quality of life score(physiological score,psychological score,social score,environmental score).Results The study group had objective effective rate of 45.16%and disease control rate of 87.10%,which were higher than 19.35%and 54.84%of the reference group(P<0.05).After treatment,the study group had CD3^(+)of(55.65±7.86)%and CD4^(+)of(36.29±5.49)%,which were higher than(50.16±8.42)%and(30.49±4.19)%in the reference group;the study group had CD8^(+)of(22.59±4.89)%and CD4^(+)CD25^(+)Treg of(4.36±1.08)%,which were lower than(26.15±4.36)%and(8.15±1.39)%in the reference group(P<0.05).After treatment,the physiological,psychological,social and environmental scores of the study group were(70.33±3.12),(71.44±3.25),(71.64±5.22)and(71.87±4.25)points,which were higher than(60.36±2.25),(60.64±5.15),(60.65±4.22)and(60.64±5.25)points of the reference group(P<0.05).Conclusion Adjuvant chemotherapy with Aidi injection for elderly patients with advanced non-small cell lung cancer can improve the therapeutic effect and quality of life,and improve the immune function.It can be popularized in clinical application.

关 键 词：艾迪注射液 化疗 晚期非小细胞肺癌 免疫功能 生存质量 老年 

分 类 号：R734.2[医药卫生—肿瘤]